Published in J Invest Dermatol on April 01, 2000
Candida albicans secreted aspartyl proteinases in virulence and pathogenesis. Microbiol Mol Biol Rev (2003) 4.07
Candida albicans cell wall proteins. Microbiol Mol Biol Rev (2008) 2.11
The skin barrier as an innate immune element. Semin Immunopathol (2007) 1.81
The secreted aspartyl proteinases Sap1 and Sap2 cause tissue damage in an in vitro model of vaginal candidiasis based on reconstituted human vaginal epithelium. Infect Immun (2003) 1.49
Comparison between Candida albicans agglutinin-like sequence gene expression patterns in human clinical specimens and models of vaginal candidiasis. Infect Immun (2005) 1.31
Discovery of a "white-gray-opaque" tristable phenotypic switching system in candida albicans: roles of non-genetic diversity in host adaptation. PLoS Biol (2014) 1.08
Fungal virulence studies come of age. Genome Biol (2001) 1.07
Secreted aspartic protease cleavage of Candida albicans Msb2 activates Cek1 MAPK signaling affecting biofilm formation and oropharyngeal candidiasis. PLoS One (2012) 1.06
State-of-the-art of 3D cultures (organs-on-a-chip) in safety testing and pathophysiology. ALTEX (2014) 0.94
Differential expression of secretory aspartyl proteinase genes (SAP1-10) in oral Candida albicans isolates with distinct karyotypes. J Clin Microbiol (2004) 0.90
Novel Aggregation Properties of Candida albicans Secreted Aspartyl Proteinase Sap6 Mediate Virulence in Oral Candidiasis. Infect Immun (2015) 0.88
Niche-specific requirement for hyphal wall protein 1 in virulence of Candida albicans. PLoS One (2013) 0.86
Role of Candida albicans-secreted aspartyl proteinases (Saps) in severe early childhood caries. Int J Mol Sci (2014) 0.83
Kinin release from human kininogen by 10 aspartic proteases produced by pathogenic yeast Candida albicans. BMC Microbiol (2015) 0.76
Effects of yoga exercise on salivary beta-defensin 2. Eur J Appl Physiol (2013) 0.75
Genetic variability of Candida albicans Sap8 propeptide in isolates from different types of infection. Biomed Res Int (2015) 0.75
Effects of High-Intensity Endurance Exercise on Epidermal Barriers against Microbial Invasion. J Sports Sci Med (2013) 0.75
Genomic Analyses of Cladophialophora bantiana, a Major Cause of Cerebral Phaeohyphomycosis Provides Insight into Its Lifestyle, Virulence and Adaption in Host. PLoS One (2016) 0.75
Interaction of Candida Species with the Skin. Microorganisms (2017) 0.75
A triple deletion of the secreted aspartyl proteinase genes SAP4, SAP5, and SAP6 of Candida albicans causes attenuated virulence. Infect Immun (1997) 2.35
Multiplicity of genes encoding secreted aspartic proteinases in Candida species. Mol Microbiol (1994) 2.09
Successful treatment of severe refractory atopic dermatitis with mycophenolate mofetil. Br J Dermatol (1999) 1.96
Differential expression of secreted aspartyl proteinases in a model of human oral candidosis and in patient samples from the oral cavity. Mol Microbiol (1998) 1.70
Secreted aspartic proteinase (Sap) activity contributes to tissue damage in a model of human oral candidosis. Mol Microbiol (1999) 1.69
Evidence that members of the secretory aspartyl proteinase gene family, in particular SAP2, are virulence factors for Candida vaginitis. J Infect Dis (1999) 1.58
The pH of the skin surface and its impact on the barrier function. Skin Pharmacol Physiol (2006) 1.55
Systemic fungal infections caused by Candida species: epidemiology, infection process and virulence attributes. Curr Drug Targets (2005) 1.48
Invasion of human keratinocytes by Staphylococcus aureus and intracellular bacterial persistence represent haemolysin-independent virulence mechanisms that are followed by features of necrotic and apoptotic keratinocyte cell death. Br J Dermatol (2002) 1.42
[Pyoderma]. Hautarzt (1998) 1.37
Molecular analysis of CaMnt1p, a mannosyl transferase important for adhesion and virulence of Candida albicans. Proc Natl Acad Sci U S A (1998) 1.36
Differential regulation of SAP8 and SAP9, which encode two new members of the secreted aspartic proteinase family in Candida albicans. Microbiology (1998) 1.35
Secreted aspartyl proteinases and interactions of Candida albicans with human endothelial cells. Infect Immun (1998) 1.31
Glucosylceramide synthases, a gene family responsible for the biosynthesis of glucosphingolipids in animals, plants, and fungi. J Biol Chem (2001) 1.28
Influence of serum protein binding on the in vitro activity of anti-fungal agents. Infection (1996) 1.23
CandidaDB: a genome database for Candida albicans pathogenomics. Nucleic Acids Res (2005) 1.23
Germ tubes and proteinase activity contribute to virulence of Candida albicans in murine peritonitis. Infect Immun (1999) 1.22
Hyaluronic acid in the treatment and prevention of skin diseases: molecular biological, pharmaceutical and clinical aspects. Skin Pharmacol Physiol (2004) 1.19
Late cutaneous schistosomiasis representing an isolated skin manifestation of schistosoma mansoni infection. Dermatology (2000) 1.19
Cloning and functional expression of UGT genes encoding sterol glucosyltransferases from Saccharomyces cerevisiae, Candida albicans, Pichia pastoris, and Dictyostelium discoideum. J Biol Chem (1999) 1.17
[Normal pH value of human skin]. Hautarzt (1986) 1.16
Mechanisms of adherence of Candida albicans to cultured human epidermal keratinocytes. Infect Immun (1993) 1.14
Influence of albumin on itraconazole and ketoconazole antifungal activity: results of a dynamic in vitro study. Antimicrob Agents Chemother (1991) 1.13
Altered adherence in strains of Candida albicans harbouring null mutations in secreted aspartic proteinase genes. FEMS Microbiol Lett (1998) 1.11
Candida glabrata persistence in mice does not depend on host immunosuppression and is unaffected by fungal amino acid auxotrophy. Infect Immun (2009) 1.10
Increased expression of Candida albicans secretory proteinase, a putative virulence factor, in isolates from human immunodeficiency virus-positive patients. J Clin Microbiol (1995) 1.07
Effects of the human immunodeficiency virus (HIV) proteinase inhibitors saquinavir and indinavir on in vitro activities of secreted aspartyl proteinases of Candida albicans isolates from HIV-infected patients. Antimicrob Agents Chemother (1999) 1.05
Characterisation of penicillinase producing gonococci isolated in Munich, 1981-6. Genitourin Med (1988) 1.02
1Alpha,25-dihydroxyvitamin D3 protects human keratinocytes from apoptosis by the formation of sphingosine-1-phosphate. J Invest Dermatol (2001) 0.99
[Morphologic variants of genital ulcer caused by Haemophilus ducreyi]. Hautarzt (1989) 0.99
Levels of itraconazole in skin blister fluid after a single oral dose and during repetitive administration. J Am Acad Dermatol (1990) 0.98
The role of vitamin E in normal and damaged skin. J Mol Med (Berl) (1995) 0.97
The genes encoding the secreted aspartyl proteinases of Candida albicans constitute a family with at least three members. Infect Immun (1993) 0.97
The role of Candida albicans secreted aspartic proteinase in the development of candidoses. J Mol Med (Berl) (1996) 0.96
Antimicrobial susceptibility testing of dermatophytes--comparison of the agar macrodilution and broth microdilution tests. Chemotherapy (1998) 0.96
Current and future approaches to antimycotic treatment in the era of resistant fungi and immunocompromised hosts. Int J Antimicrob Agents (2001) 0.95
Reconstructed epidermis versus human and animal skin in skin absorption studies. Toxicol In Vitro (2005) 0.95
Anti-microbial and -inflammatory activity and efficacy of phytosphingosine: an in vitro and in vivo study addressing acne vulgaris. Int J Cosmet Sci (2007) 0.95
Cefodizime penetration into skin suction blister fluid following a single intravenous dose. Eur J Clin Pharmacol (1986) 0.95
Onychomycosis. Mycoses (2007) 0.94
The KEX2 gene of Candida glabrata is required for cell surface integrity. Mol Microbiol (2001) 0.94
Aquarium dermatitis: cercarial dermatitis in an aquarist. Dermatology (1998) 0.93
Actinic keratosis: the key event in the evolution from photoaged skin to squamous cell carcinoma. Therapy based on pathogenetic and clinical aspects. Skin Pharmacol Physiol (2004) 0.92
Bacteriophages induced by ciprofloxacin in a Borrelia burgdorferi skin isolate. Zentralbl Bakteriol (1993) 0.92
[Ultrastructure and microflora in follicles and comedones]. Hautarzt (1976) 0.92
Plasmid content and protein I serovar of non-penicillinase-producing gonococci isolated in Munich. Epidemiol Infect (1988) 0.92
In vivo expression and localization of Candida albicans secreted aspartyl proteinases during oral candidiasis in HIV-infected patients. J Invest Dermatol (1999) 0.91
The use of systemic antimycotics in dermatotherapy. Eur J Dermatol (2000) 0.91
Preputial abscesses caused by beta-lactamase-producing gonococci. Cutis (1985) 0.90
Lipid nanoparticles for skin penetration enhancement-correlation to drug localization within the particle matrix as determined by fluorescence and parelectric spectroscopy. J Control Release (2005) 0.90
Game theoretical modelling of survival strategies of Candida albicans inside macrophages. J Theor Biol (2010) 0.89
Efficacy and safety of a new single-dose terbinafine 1% formulation in patients with tinea pedis (athlete's foot): a randomized, double-blind, placebo-controlled study. J Eur Acad Dermatol Venereol (2006) 0.89
Liposomes: a drug carrier system for topical treatment in dermatology. Crit Rev Ther Drug Carrier Syst (1994) 0.89
[The correlation between biotype and antifungal sensitivity of Candida albicans]. Mykosen (1987) 0.89
Phospholipases of Candida albicans. Mycoses (2001) 0.88
Influence of repeated washings with soap and synthetic detergents on pH and resident flora of the skin of forehead and forearm. Results of a cross-over trial in health probationers. Acta Derm Venereol (1987) 0.88
RU 58841-myristate--prodrug development for topical treatment of acne and androgenetic alopecia. Pharmazie (2005) 0.88
A method for recovery of Candida albicans DNA from larger blood samples and its detection by polymerase chain reaction on proteinase genes. Mycoses (1997) 0.88
In vitro activity of eight antimicrobial agents against non-penicillinase-producing gonococci isolated in Munich. Genitourin Med (1988) 0.87
Persistent oral candidosis by non-albicans Candida strains including Candida glabrata in a human immunodeficiency virus-infected patient observed over a period of 6 years. Mycoses (1999) 0.87
HIV protease inhibitors influence the prevalence of oral candidosis in HIV-infected patients: a 2-year study. Mycoses (1999) 0.87
Drug targeting by solid lipid nanoparticles for dermal use. J Drug Target (2002) 0.87
Human plasma and skin blister fluid levels of griseofulvin following a single oral dose. Eur J Clin Pharmacol (1985) 0.87
Repeated exposition to subinhibitory concentrations of antibiotic in vitro readily decreases susceptibility of Neisseria gonorrhoeae to rifampicin, but not to new cephalosporins and penicillin G. Chemotherapy (1984) 0.86
Management of onychomycoses. Drugs (1999) 0.86
Susceptibility of Neisseria gonorrhoeae to ceftizoxime in vitro and in vivo. Chemotherapy (1984) 0.86
Prevalence of gonococci lacking the 2.6 megadalton cryptic plasmid. Lancet (1987) 0.85
Ketoconazole concentrations in human skin blister fluid and plasma. Int J Clin Pharmacol Ther Toxicol (1984) 0.85
Deep subcutaneous application of poly-L-lactic acid as a filler for facial lipoatrophy in HIV-infected patients. Skin Pharmacol Physiol (2005) 0.85
Does cantharides blister fluid provide access to the peripheral compartment? Eur J Clin Pharmacol (1982) 0.85
Evaluation of cefotetan in uncomplicated gonorrhea. Dermatologica (1986) 0.84
Comparative efficacy and safety of bifonazole 1% cream and the corresponding base preparation in the treatment of seborrhoeic dermatitis. Mycoses (1994) 0.84
[Antimicrobial effects of in vitro-simulated ketoconazole-cantharidin blister fluid levels on candida albicans]. Mykosen (1986) 0.84
Effect of iron limitation on protein composition and ultrastructure of Haemophilus ducreyi. FEMS Microbiol Lett (1990) 0.84
Mechanisms of skin adherence, penetration and tissue necrosis production by Haemophilus ducreyi, the causative agent of chancroid. Acta Derm Venereol Suppl (Stockh) (1992) 0.84
Molecular and phenotypic identification of the yeast pathogen Candida dubliniensis. J Mol Med (Berl) (2000) 0.83
Innate immune receptors on neutrophils and their role in chronic lung disease. Eur J Clin Invest (2009) 0.83
Reflectance confocal microscopy in the diagnosis of partially and completely amelanotic melanoma: report on seven cases. J Eur Acad Dermatol Venereol (2012) 0.83
Penciclovir cream--improved topical treatment for herpes simplex infections. Skin Pharmacol Physiol (2004) 0.83
Dubowitz syndrome: atopic dermatitis, low birth weight dwarfism and facial dysmorphism. Dermatologica (1990) 0.83
Sunscreens - which and what for? Skin Pharmacol Physiol (2005) 0.83
Immunohistochemical investigations of genital ulcers caused by Haemophilus ducreyi. Int J STD AIDS (1997) 0.83
Glucocorticoid entrapment into lipid carriers--characterisation by parelectric spectroscopy and influence on dermal uptake. J Control Release (2004) 0.83
Comparative atrophogenicity potential of medium and highly potent topical glucocorticoids in cream and ointment according to ultrasound analysis. Skin Pharmacol (1992) 0.83
Liposomes for atopic dry skin: the rationale for a promising approach. Clin Investig (1993) 0.82
In vivo assessment of the atrophogenic potency of mometasone furoate, a newly developed chlorinated potent topical glucocorticoid as compared to other topical glucocorticoids old and new. Int J Clin Pharmacol Ther (1995) 0.82
Absence of extracellular enzyme activity and cytotoxicity in cell-free culture filtrates of Haemophilus ducreyi. Microb Pathog (1991) 0.82
Folliculitis decalvans. Long-lasting response to combined therapy with fusidic acid and zinc. Acta Derm Venereol (1992) 0.82
Distribution of auxotypes and correlation to antibiotic susceptibility of 169 recent clinical Neisseria gonorrhoeae isolates from Munich. Arch Dermatol Res (1983) 0.82
In vitro investigations on the mode of action of the hydroxypyridone antimycotics rilopirox and piroctone on Candida albicans. Mycoses (2006) 0.82
Interaction of cultured human keratinocytes with liposomes encapsulating silver sulphadiazine: proof of the uptake of intact vesicles. Br J Dermatol (1996) 0.82
The secreted aspartic proteinases as a new target in the therapy of candidiasis. Curr Drug Targets (2002) 0.82
Tazarotene: therapeutic strategies in the treatment of psoriasis, acne and photoaging. Skin Pharmacol Physiol (2004) 0.82
Human plasma and skin blister fluid levels of griseofulvin after its repeated administration. Eur J Clin Pharmacol (1985) 0.82